Recently, sirolimus, a rapamycin (mTOR) inhibitor, offers promising treatment results in patients with complex LMs.[12] Adverse effects are dose dependent and include hypertension, dyslipidemia, poor wound healing, bone marrow suppression (neutropenia, anemia, thrombocytopenia), and increased susceptibility to infections. Here, MTOR is linked to anemia (phenotype).